Omicron, a new SARS-CoV-2 variant: assessing the impact on severity and vaccines efficacy
The reply letter has been put forth in response to the comment made by Karthyayani Priya Satish entitled “India and the COVID-19 Vaccine.” The comment was made in context to our published work “Exploring the covid-19 vaccine candidates against SARS-CoV-2 and its variants: where do we stand and where...
Gorde:
| Egile Nagusiak: | , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Taylor & Francis Group
2022-01-01
|
| Saila: | Human Vaccines & Immunotherapeutics |
| Gaiak: | |
| Sarrera elektronikoa: | http://dx.doi.org/10.1080/21645515.2022.2034458 |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|